

Lunate

30/06/2026

Mr. Abdulla Salem Al Nuaimi

CEO

Abu Dhabi Securities Exchange (ADX)

Abu Dhabi, United Arab Emirates

Greetings,


Subject: Change of Name of the ICAV and its Sub-Funds

Dear Shareholder.

In accordance with the applicable Listing and Disclosure Rules, we would like to inform you that the name of the ICAV and its Sub-Funds has been changed, effective 1 July 2026, as set out in the table below:

Name Before Change	Name After Change
Chimera UCITS ICAV	Lunate UCITS ICAV
Chimera S&P UAE UCITS ETF - Share D - Income	Lunate S&P UAE UCITS ETF - Share D - Income
Chimera S&P Pakistan UCITS ETF- Share D - Income	Lunate S&P Pakistan UCITS ETF- Share D - Income
Chimera S&P Germany UCITS ETF- Share D - Income	Lunate S&P Germany UCITS ETF- Share D - Income
Chimera S&P Japan UCITS ETF- Share D - Income	Lunate S&P Japan UCITS ETF- Share D - Income
Chimera JP Morgan UAE Bond UCITS ETF- Share D - Income	Lunate JP Morgan UAE Bond UCITS ETF- Share D - Income

Kindly see enclosed the ICAV's letter on the matter.


Sherif Salem
Head of Public Markets



LUNATE CAPITAL LIMITED
12TH FLOOR, ALMAYYAH TOWER,
ABU DHABI,
UNITED ARAB EMIRATES
LUNATE.COM

Lunate Capital Limited is duly licensed and regulated by the ADGM Financial Services Regulatory Authority

CHIMERA UCITS ICAV

10 Earlsfort Terrace
Dublin 2, D02 T380
Ireland

Date: 11 June 2026

This letter is important and should be read now. If you are unsure what action to take, please seek advice from your investment consultant or other professional adviser.

If you have sold or transferred all of your Shares in Chimera UCITS ICAV (the “ICAV”) or any of the sub-funds subject to this letter (each a “Fund” and, together, the “Funds”), please pass this letter at once to the purchaser or transferee or to the stockbroker, bank, or other agent you used to sell or transfer the Shares.

Capitalised terms used herein shall bear the same meaning as capitalised terms used in the prospectus for the ICAV dated 12 September 2025, as may be amended or supplemented from time to time (the “Prospectus”) and the supplement for the relevant Fund (each a “Supplement”). Copies of the Prospectus and the Supplement are available upon request during normal business hours from the registered office of the ICAV or from the local representative of the ICAV in each jurisdiction in which the Fund is registered for public distribution.

Please note that the Central Bank has not reviewed this letter.

Dear Shareholder,

The purpose of this letter is to inform you of proposed changes to the names of the ICAV and the Funds listed in the table below with effect from 1 July 2026, subject to the approval of the Central Bank.

It is proposed to change the name of the ICAV and the Funds as follows:

Current Name	Proposed New Name
Chimera UCITS ICAV	Lunate UCITS ICAV
Chimera S&P UAE UCITS ETF	Lunate S&P UAE UCITS ETF
Chimera S&P Pakistan UCITS ETF	Lunate S&P Pakistan UCITS ETF
Chimera S&P Germany UCITS ETF	Lunate S&P Germany UCITS ETF
Chimera S&P Japan UCITS ETF	Lunate S&P Japan UCITS ETF
Chimera JP Morgan UAE Bond UCITS ETF	Lunate JP Morgan UAE Bond UCITS ETF

The proposed changes to the names of the ICAV and the Funds reflect the rebranding of the Investment Manager to “Lunate Capital Limited” and seeks to align the ICAV and the Funds under a consistent brand with the Investment Manager. The proposed changes to the names of the ICAV and the Funds will not result in any changes to the investment objectives or policies of any Fund nor the manner in which any Fund is managed.

Effective Date of Changes

The proposed changes to the names of the ICAV and the Funds will take effect on the filing of a revised Prospectus with the Central Bank on or about 1 July 2026.

Repurchase Of Shares

Shareholders who do not wish to remain invested in a Fund following the implementation of the changes set out above will have the opportunity to redeem their Shares on any Dealing Day prior to the effective date of the changes by following the usual repurchase procedures as set out in the Prospectus.

Conclusion

Should you have any questions relating to these matters, you should either contact us at the above address or alternatively you should contact your investment consultant.

Yours faithfully,

A handwritten signature in black ink, appearing to be 'L. J. W. Jones', written over a horizontal line.

Director
For and on behalf of
Chimera UCITS ICAV